Company profile
Monopar Therapeutics Inc.
NASDAQ: MNPR · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
59CFH 73DQ 40GM —SS 50
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$13.7M
Employees
22
as of 2026-08-11
Market cap
$779.4M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$13.7M-$13.7M2025
Operating income-$16.7M-$16.7M2025
Total assets$140.7M$140.7M2025
Liabilities$2.9M$2.9M2025
Equity$137.8M$137.8M2025
Revenue trend
FY2017 – FY2025 · USD
FY17
FY17
FY18
FY19
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Monopar Therapeutics Inc.’s revenue?
Monopar Therapeutics Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Kardigan, Inc.——Cullinan Therapeutics, Inc.50DDesign Therapeutics, Inc.55CAllogene Therapeutics, Inc.39DAchieve Life Sciences, Inc.37DNeurogene Inc.43DNeighbors
Cook →Key facts
CEOChandler D. Robinson
SectorHealthcare
IndustryBiotechnology
HeadquartersWilmette, IL
ExchangeNASDAQ: MNPR
Employees22
IPO date2019-12-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.